Endocannabinoids modulate human blood-brain barrier permeability in vitro

British Journal of Pharmacology

Volumn 172, Issue 12, 2015, Pages 3015-3027

  Hind, William H ^a   Tufarelli, Cristina ^a   Neophytou, Maria ^a   Anderson, Susan I ^a   England, Timothy J ^a   O'Sullivan, Saoirse E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; N ARACHIDONOYL DOPAMINE; N OLEOYLETHANOLAMINE; NOLADIN ETHER; OLEAMIDE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VIRODHAMINE; AMIDE; ARACHIDONIC ACID DERIVATIVE; MESSENGER RNA; OLEIC ACID;

ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CAPILLARY ENDOTHELIAL CELL; CB2 RECEPTOR GENE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; NERVE CELL CULTURE; NEUROMODULATION; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION; TARGET CELL; CELL CULTURE; COCULTURE; ENDOTHELIUM CELL; IMPEDANCE; METABOLISM; PERMEABILITY; REPERFUSION INJURY;

ARACHIDONIC ACIDS; ASTROCYTES; BLOOD-BRAIN BARRIER; CELLS, CULTURED; COCULTURE TECHNIQUES; ELECTRIC IMPEDANCE; ENDOCANNABINOIDS; ENDOTHELIAL CELLS; HUMANS; OLEIC ACIDS; PERMEABILITY; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB2; REPERFUSION INJURY; RNA, MESSENGER;

EID: 84930206791     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13106     Document Type: Article

References (54)

1. Abbott NJ, (2002). Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 200: 629-638.
2. Ahmad A, Crupi R, Impellizzeri D, Campolo M, Marino A, Esposito E, et al. (2012a). Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav Immun 26: 1310-1321.
3. Ahmad A, Genovese T, Impellizzeri D, Crupi R, Velardi E, Marino A, et al. (2012b). Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. Brain Res 1477: 45-58.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675
7. Alexander SP, Kendall DA, (2007). The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152: 602-623.
8. Alhamoruni A, Lee AC, Wright KL, Larvin M, O'Sullivan SE, (2010). Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J Pharmacol Exp Ther 335: 92-102.
9. Alhamoruni A1, Wright KL, Larvin M, O'Sullivan SE, (2012). Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br J Pharmacol 165: 2598-2610.
10. Allen CL, Bayraktutan U, (2009). Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood-brain barrier hyperpermeability. Diabetes Obes Metab 11: 480-490.
11. Amenta PS, Jallo JI, Tuma RF, Elliott MB, (2012). A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J Neurosci Res 90: 2293-2305.
12. Cencioni MT1, Chiurchiù V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, et al. (2010). Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 5: e8688.
13. Console-Bram L, Marcu J, Abood ME, (2012). Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry 38: 4-15.
14. Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, et al. (2003). Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23: 6264-6271.
15. Dong YL, Fang L, Kondapaka S, Gangula PR, Wimalawansa SJ, Yallampalli C, (1999). Involvement of calcitonin gene-related peptide in the modulation of human myometrial contractility during pregnancy. J Clin Invest 104: 559-565.
16. Fowler CJ, (2013). Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J 280: 1895-1904.
17. Fowler CJ, Tiger G, Ligresti A, Lopez-Rodriguez ML, Di Marzo V, (2004). Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis-a difficult issue to handle. Eur J Pharmacol 492: 1-11.
18. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, et al. (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132: 87-92.
19. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R, (1996). 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 53: 309-315.
20. Hillard CJ, (2008). Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des 14: 2347-2361.
21. Huang W, Eum SY, Andras IE, Hennig B, Toborek M, (2009). PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J 23: 1596-1606.
22. Kaczocha M, Vivieca S, Sun J, Glaser SJ, Deutsch DG, (2012). Fatty acid-binding proteins transport n-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. J Biol Chem 287: 3415-3424.
23. Kenakin T, (2009). Biased agonism. F1000 Biol Rep 1: 87.
24. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA, (2003). Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 34: 2543-2548.
25. Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S, (2004). Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 56: 468-477.
26. Liu Z, Liu Q, Cai H, Xu C, Liu G, Li Z, (2011). Calcitonin gene-related peptide prevents blood-brain barrier injury and brain edema induced by focal cerebral ischemia reperfusion. Regul Pept 171: 19-25.
27. Lo EH, Dalkara T, Moskowitz MA, (2003). Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4: 399-415.
28. Luo D, Zhang YW, Peng WJ, Peng J, Chen QQ, Li D, et al. (2008). Transient receptor potential vanilloid 1-mediated expression and secretion of endothelial cell-derived calcitonin gene-related peptide. Regul Pept 150: 66-72.
29. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J, (1999). PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131.
30. McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA, (2008). Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol 73: 441-450.
31. Mestre L, Inigo PM, Mecha M, Correa FG, Hernangomez-Herrero M, Loria F, et al. (2011). Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors. J Neuroinflammation 8: 102.
32. Mysiorek C, Culot M, Dehouck L, Derudas B, Staels B, Bordet R, et al. (2009). Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier. Curr Neurovasc Res 6: 181-193.
33. Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, et al. (2010). Possible anandamide and palmitoylethanolamide involvement in human stroke. Lipids Health Dis 9: 47.
34. Nagasawa K, Chiba H, Fujita H, Kojima T, Saito T, Endo T, et al. (2006). Possible involvement of gap junctions in the barrier function of tight junctions of brain and lung endothelial cells. J Cell Physiol 208: 123-132.
35. O'Sullivan SE, (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152: 576-582.
36. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. (2006). The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22: 257-264.
37. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
38. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 62: 588-631.
39. Ramirez SH, Hasko J, Skuba A, Fan S, Dykstra H, McCormick R, et al. (2012). Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci 32: 4004-4016.
40. Reynders V, Loitsch S, Steinhauer C, Wagner T, Steinhilber D, Bargon J, (2006). Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes. Respir Res 30: 104.
41. Saunders CI, Fassett RG, Geraghty DP, (2009). Up-regulation of TRPV1 in mononuclear cells of end-stage kidney disease patients increases susceptibility to N-arachidonoyl-dopamine (NADA)-induced cell death. Biochim Biophys Acta 1792: 1019-1026.
42. Schabitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, et al. (2002). Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 33: 2112-2114.
43. Schley M, Ständer S, Kerner J, Vajkoczy P, Schüpfer G, Dusch M, et al. (2009). Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull 79: 333-337.
44. Snider NT1, Nast JA, Tesmer LA, Hollenberg PF, (2009). A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. Mol Pharmacol 75: 965-972.
45. Spinsanti G, Zannolli R, Panti C, Ceccarelli I, Marsili L, Bachiocco V, et al. (2008). Quantitative real-time PCR detection of TRPV1-4 gene expression in human leukocytes from healthy and hyposensitive subjects. Mol Pain 4: 51.
46. Sughrue ME, Mehra A, Connolly ES Jr, D'Ambrosio AL, (2004). Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: a critical review of the literature. Inflamm Res 53: 497-508.
47. Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, et al. (2007). Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 152: 734-743.
48. Walker JM, Krey JF, Chu CJ, Huang SM, (2002). Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 121: 159-172.
49. Wang Q, Peng Y, Chen S, Gou X, Hu B, Du J, et al. (2009). Pretreatment with electroacupuncture induces rapid tolerance to focal cerebral ischemia through regulation of endocannabinoid system. Stroke 40: 2157-2164.
50. Watanabe H1, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B, (2003). Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424: 434-438.
51. Wojtalla A, Herweck F, Granzow M, Klein S, Trebicka J, Huss S, et al. (2012). The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes. Am J Physiol Gastrointest Liver Physiol 302: G873-G887.
52. Zhang H1, Hilton DA, Hanemann CO, Zajicek J, (2011). Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D-evidence for altered expression in multiple sclerosis. Brain Pathol 21: 544-557.
53. Zhou Y, Yang L, Ma A, Zhang X, Li W, Yang W, et al. (2012). Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor alpha. Neuropharmacology 63: 242-249.
54. Zygmunt PM1, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457.